US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Landcadia Holdings IV Inc

10.54

+0.0000

Volume:- -

Turnover:- -

Market Cap:142.91M

PE:103.68

High:10.54

Open:10.54

Low:10.54

Close:10.54

Loading ...

Overview Company News Filings

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

Preliminary Results for the Year Ended 31 December 2024

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

UNIFI®, Makers of REPREVE®, Announces Eighth Annual Champions of Sustainability Award Winners

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Press Release: Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Atos Belgium and Venator Announce the Successful Implementation of the Eviden Product Carbon Footprint Platform

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Cisco Sustainability 101: What Are Life Cycle Assessments?

ACCESS Newswire

Sonoco’s EnviroCan® with a Metal Bottom Receives Pre-qualification for How2Recycle® Labeling

M0.0NSHOT Zero, the world’s first net zero carbon shoe, pushes the boundaries of sustainable footwear

Geely Starts Selling Electric Cars in Indonesia, Booking Fee Rp10,000

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Hyundai Motor, Kia Unveil Integrated Greenhouse Gas Information System

MT Newswires Live

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LCA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LCA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LCA\",,,,,undefined,":{"symbol":"LCA","market":"US","secType":"STK","nameCN":"Landcadia Holdings IV Inc","latestPrice":10.54,"timestamp":1745611200000,"preClose":10.54,"halted":0,"volume":0,"delay":0,"floatShares":1058523,"shares":13558523,"eps":0.101663,"marketStatus":"Closed","change":0,"latestTime":"04-25 16:00:00 EDT","open":10.54,"high":10.54,"low":10.54,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.101663,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":10.54,"volumeRatio":0,"impliedVol":1.24,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LCA\",,,,,undefined,":{"symbol":"LCA","floatShares":1058523,"roa":"-0.31%","roe":"--","lyrEps":0.385996,"shares":13558523,"dividePrice":0,"high":10.54,"amplitude":0,"preClose":10.54,"low":10.54,"week52Low":10.54,"pbRate":"-24.43","week52High":10.54,"institutionHeld":0,"latestPrice":10.54,"eps":0.101663,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.101663,"open":10.54,"prevYearClose":10.54,"prevWeekClose":10.54,"prevMonthClose":10.54,"prevQuarterClose":10.54,"fiveDayClose":10.54,"twentyDayClose":10.54,"sixtyDayClose":10.54},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LCA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527457964","title":"PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath","url":"https://stock-news.laohu8.com/highlight/detail?id=2527457964","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527457964?lang=en_us&edition=fundamental","pubTime":"2025-04-15 22:36","pubTimestamp":1744727760,"startTime":"0","endTime":"0","summary":"Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic Programs. NEW YORK, April 15, 2025  -- PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc.  , a clinical-stage gene therapy company developing treatments for inherited retinal diseases  and broader ophthalmic conditions.Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc.In the interview, Dr. Magrath outlines Opus Genetics’ recent milestones, including:. Completion of enrollment in two Phase 3 clinical trials: VEGA-3 for presbyopia and LYNX-2 for post-LASIK night vision disturbances;FDA Fast Track designation for phentolamine ophthalmic solution to treat chronic night driving impairment; and. Upcoming data presentations for OPGx-LCA5, an AAV-based gene therapy targeting Leber congenital amaurosis 5.The feature also explores Opus Genetics’ strategy to seek to build a repeatable gene therapy platform and anticipated clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prism-marketview-spotlights-opus-genetics-143600589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4141","IRD","MMAT","LCA","BK4007"],"gpt_icon":0},{"id":"2526066623","title":"Preliminary Results for the Year Ended 31 December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2526066623","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526066623?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:30","pubTimestamp":1744374600,"startTime":"0","endTime":"0","summary":"April 11, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/11/3060077/0/en/Preliminary-Results-for-the-Year-Ended-31-December-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4211","LCA","PFS","BK4097","BK4195","BK4139","BDRX"],"gpt_icon":1},{"id":"2525993228","title":"Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2525993228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525993228?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is exp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057520/0/en/Opus-Genetics-Announces-One-Month-Clinical-Data-from-Pediatric-Patient-in-Phase-1-2-Trial-of-OPGx-LCA5-Gene-Therapy-in-Inherited-Retinal-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BKVL7J92.USD","SAP","LU0882574139.USD","LU1363072403.SGD","LU0149725797.USD","LU0170899867.USD","IE00BHPRN162.USD","IE00BZ1G4Q59.USD","LU0971096721.USD","CMC","BK4585","LCA","BK4023","LU0267386448.USD","BK4528","BK4613","IRD","IE00B1BXHZ80.USD","BK4006","BK4007","KOL"],"gpt_icon":0},{"id":"2524523122","title":"UNIFI®, Makers of REPREVE®, Announces Eighth Annual Champions of Sustainability Award Winners","url":"https://stock-news.laohu8.com/highlight/detail?id=2524523122","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524523122?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:00","pubTimestamp":1743685200,"startTime":"0","endTime":"0","summary":"Global brand, retail, and textile partners, including NIKE and Target, receive honors for their sustainability efforts and growing adoption of textile-to-textile recycling. GREENSBORO, N.C., April 03, 2025----UNIFI, Inc. , the makers of REPREVE and one of the world’s leading innovators in recycled and synthetic yarns, celebrates leading brands who helped contribute to recycling over 42 billion plastic bottles and reducing greenhouse gas emissions by avoiding 1.3 billion kilograms of carbon dioxide equivalents.The eighth annual REPREVE Champions of Sustainability awards recognize brands driving sustainability including New Balance, Free Country, Swannies, and Walmart. For the first time, the awards honor advancements in textile-to-textile recycling, including pioneers Marmot and Faherty for their contributions to circularity.Newcomer Award: Free Country, Swannies for surpassing 10 million bottles recycled. Made in the USA Award: New Balance, Signet Mills for their commitment to crafting","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unifi-makers-repreve-announces-eighth-130000160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4566","LU0786609619.USD","BK4146","MJ","BK4581","LU1303367103.USD","BK4561","BK4010","LU2098885051.SGD","BK4588","BK4558","BK4533","NKE","UFI","LU0823411888.USD","LCA","BK4534"],"gpt_icon":1},{"id":"2524460466","title":"Opus Genetics to Participate in Upcoming Investor Conference in April","url":"https://stock-news.laohu8.com/highlight/detail?id=2524460466","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524460466?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:00","pubTimestamp":1743595200,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., April 02, 2025  -- Opus Genetics, Inc. , a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases  and therapies for other ophthalmic disorders, today announced that George Magrath, M.D., Chief Executive Officer, will participate in the following upcoming investor conference in April.This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning data from our clinical trials.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-participate-upcoming-investor-120000365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IRD","BK4007","LCA"],"gpt_icon":0},{"id":"2523946439","title":"Opus Genetics Announces Financial Results for Full Year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946439","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946439?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:20","pubTimestamp":1743423600,"startTime":"0","endTime":"0","summary":"Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supple","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052265/0/en/Opus-Genetics-Announces-Financial-Results-for-Full-Year-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2521284278","title":"Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX","url":"https://stock-news.laohu8.com/highlight/detail?id=2521284278","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521284278?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:30","pubTimestamp":1742563800,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., March  21, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/21/3047093/0/en/Opus-Genetics-Announces-Presentation-on-Phentolamine-Ophthalmic-Solution-0-75-in-Dim-Light-Disturbances-at-World-Cornea-Congress-IX.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","BK4184","IX"],"gpt_icon":0},{"id":"2521281557","title":"Press Release: Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521281557","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521281557?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:11","pubTimestamp":1742562660,"startTime":"0","endTime":"0","summary":"Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million. The concurrent private placement is comprised of 1,176,471 shares of common stock and 1,176,471 warrants to purchase shares of common stock, at an offering price of $1.275. The warrants will be exercisable immediately upon issuance, have an initial exercise price of $1.15, expire on the five-year anniversary of the original issuance date and may be called by the Company 30 days following the release of the Company's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of a volume weighted average price of o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","IRD","BK4007"],"gpt_icon":0},{"id":"2518235066","title":"Atos Belgium and Venator Announce the Successful Implementation of the Eviden Product Carbon Footprint Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2518235066","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518235066?lang=en_us&edition=fundamental","pubTime":"2025-03-12 17:00","pubTimestamp":1741770000,"startTime":"0","endTime":"0","summary":"Brussels, Belgium, and Paris, France – March 12, 2025 – Atos Belgium is pleased to announce the successful rollout by Eviden, its business group leading in digital, cloud, big data and security, of its Product Carbon Footprint  Platform at Venator, a global manufacturer of titanium dioxide pigments and performance additives. This milestone marks the completion of a project that began in October 2023 and concluded in December 2024.Rob Portsmouth, Executive Vice President, EHS, Sustainability and HR at Venator, commented: “The successful implementation of the Eviden PCF Platform is a significant milestone in our sustainability journey. This advanced tool not only enhances our ability to measure and manage the carbon footprint of our products but also supports our commitment","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atos-belgium-venator-announce-successful-090000667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LCA","AEXAY","BK4134","AEXAF","PCF"],"gpt_icon":0},{"id":"2517775919","title":"Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517775919","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517775919?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:00","pubTimestamp":1741179600,"startTime":"0","endTime":"0","summary":"New Data from First Three Adult Patients in Phase 1/2 Trial with OPGx-LCA5 Showed that Subjective and Objective Signs of Efficacy Persisted for One Year. Durham, NC., March 05, 2025  -- Opus Genetics, Inc. , a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases  and other ophthalmologic disorders, today announced that three abstracts on its investigational gene therapy candidates have been accepted for presentation at the Association for Research in Vision and Ophthalmology 2025 Meeting, to take place May 4-8, 2025 in Salt Lake City, UT. The abstracts feature 12-month data from the first three adult patients in our ongoing Phase 1/2 trial of OPGx-LCA5, as well as pre-clinical results on OPGx-MERTK and OPGx-RDH12.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-announces-presentations-association-130000355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IRD","LCA"],"gpt_icon":0},{"id":"2514320488","title":"Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320488","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514320488?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Enrollment completion in LYNX-2 pivotal Phase 3 trial expected in first half of 2025. Enrollment now complete in VEGA-3 pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia. VEGA-3 is a randomized, double-masked, placebo-controlled, multi-center, Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% in 545 participants with presbyopia. The primary endpoint is the percentage of participants with 15-letter improvement in photopic binocular distance-corrected near visual acuity  on the eighth day following their first visit. Participants are being followed a total of 48 weeks to collect chronic safety data. Recruitment has taken place","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-announces-fda-fast-130000009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IE00BFXG0V08.USD","IE00B5TLWC47.USD","IE00BYQQ9H92.USD","LCA","IRD","BK4585","FAST","BK4567","BK4104","BK4588"],"gpt_icon":0},{"id":"2512151008","title":"Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2512151008","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512151008?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:30","pubTimestamp":1739881800,"startTime":"0","endTime":"0","summary":"First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and registrational endpoints for OPGx-LCA5. This clinical trial was designed to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-LCA5 in patients with inherited retinal degeneration due to biallelic mutations in theLCA5gene. It is an open-label, Phase 1/2 trial evaluating OPGx-LCA5. Efficacy endpoints include measurement of functional vision using: 1) the Multi-Luminance orientation and Mobility Test ; 2) Full-Field Stimulus Testing , which measures the re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-announces-updates-opgx-123000259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IRD","BK4007","KOL","LCA"],"gpt_icon":0},{"id":"2509271227","title":"Cisco Sustainability 101: What Are Life Cycle Assessments?","url":"https://stock-news.laohu8.com/highlight/detail?id=2509271227","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509271227?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:00","pubTimestamp":1738850400,"startTime":"0","endTime":"0","summary":"NORTHAMPTON, MA / ACCESS Newswire / February 6, 2025 / Cisco Systems:. Do you feel a bit lost when people refer to certain environmental sustainability topics and aren't sure where to start when it comes to learning more?Sustainability 101 is a blog series that you can turn to for information about different environmental terms that may come up at work, during discussions with friends, and even at your annual holiday gathering.Every product has a story. From the raw materials used to create it, to the energy it consumes, to where it ends up when it's no longer useful- each stage impacts the environment. Life Cycle Assessments, or LCAs, help us estimate that impact and identify areas for improvement throughout a product's life cycle.LCAs help businesses understand the environmental footprint of their products, processes, or services across every stage of their life cycle. From energy use to water consumption, LCAs reveal critical data that can drive more sustainable decisions.Primary En","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cisco-sustainability-101-life-cycle-140000678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1506573853.SGD","LU0868494708.USD","BK4121","LU2237443895.HKD","LU2247934214.USD","LU1046421795.USD","IE00BGHQF631.EUR","LU0823417653.USD","IE00BKVL7J92.USD","LU1430594728.SGD","BK4585","BK4560","LU1894683264.USD","LU2237443622.USD","LU1585245621.USD","LU1066051811.HKD","LCA","LU1894683348.USD","BK4581","IE00BZ1G4Q59.USD","ISO","LU1880398554.USD","SG9999015945.SGD","BK4534","LU2506951875.HKD","LU1244550577.SGD","LU1883839398.USD","LU2237443465.HKD","SG9999015952.SGD","LU0823417737.USD","LU1244550494.USD","SG9999015978.USD","SG9999015986.USD","CSCO","BK4515","IE00B3PB1722.GBP","BK4550","LU0950375773.USD","LU2237443382.USD","LU1066053197.SGD","LU0234572021.USD","LU1571399168.USD","SG9999002224.SGD","LU0731783394.SGD","LU0234570918.USD","LU2506952097.USD","IE00BFMHRM44.USD","SG9999002232.USD","IE00B42XCP33.USD","LU2237443549.SGD"],"gpt_icon":0},{"id":"2508672145","title":"Sonoco’s EnviroCan® with a Metal Bottom Receives Pre-qualification for How2Recycle® Labeling","url":"https://stock-news.laohu8.com/highlight/detail?id=2508672145","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508672145?lang=en_us&edition=fundamental","pubTime":"2025-02-03 22:00","pubTimestamp":1738591200,"startTime":"0","endTime":"0","summary":"HARTSVILLE, S.C., Feb.  03, 2025  (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco”) (NYSE: SON), a global leader in high-value sustainable packaging, has received pre-qualification to carry the H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/03/3019585/26553/en/Sonoco-s-EnviroCan-with-a-Metal-Bottom-Receives-Pre-qualification-for-How2Recycle-Labeling.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4136","SON","LCA"],"gpt_icon":1},{"id":"2508192314","title":"M0.0NSHOT Zero, the world’s first net zero carbon shoe, pushes the boundaries of sustainable footwear","url":"https://stock-news.laohu8.com/highlight/detail?id=2508192314","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508192314?lang=en_us&edition=fundamental","pubTime":"2025-02-03 16:01","pubTimestamp":1738569660,"startTime":"0","endTime":"0","summary":"Available to buy for the first time, the style combines Allbirds’ minimalist design principles with regenerative farming practices to achieve a landmark footprintSAN FRANCISCO, Feb.  03, 2025  (GLOBE ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/03/3019225/0/en/M0-0NSHOT-Zero-the-world-s-first-net-zero-carbon-shoe-pushes-the-boundaries-of-sustainable-footwear.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","BIRD","BK4146"],"gpt_icon":0},{"id":"2505059666","title":"Geely Starts Selling Electric Cars in Indonesia, Booking Fee Rp10,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2505059666","media":"Tempo","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505059666?lang=en_us&edition=fundamental","pubTime":"2025-01-23 11:52","pubTimestamp":1737604364,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -Chinese car manufacturer, Geely, has started marketing its first car, the EX5, in Indonesia. The opening of orders for this electric car also marks Geely's presence in the automotive market in Indonesia.\"This launch marks a new chapter in Geely's journey as a global leader in intelligent mobility,\" said Vice President of Geely Auto Internasional Corporation, Evin Ya at the launch event in Jakarta, Wednesday, January 22, 2025.Geely Indonesia itself has not yet revealed the official specifications of the EX5 electric car. However, it is stated that this car is built with the GEA New Energy Architecture architecture, which is claimed to have a 40 percent longer battery life.","market":"nz","thumbnail":"https://statik.tempo.co/data/2025/01/23/id_1371713/1371713_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/01/23/id_1371713/1371713_720.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/1967205/geely-starts-selling-electric-cars-in-indonesia-booking-fee-rp10000","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["ABNB","IE0004445239.USD","BK4142","LU0942090050.USD","LU1043141123.HKD","LU1571399168.USD","BK7097","DOW.AU","IE00BSNM7G36.USD","BSD","LCA","LU0345774391.USD","LU0426417589.USD","BKNG","BK4505","LU0029864427.USD","LU0345774631.USD","TSI","LU0082616367.USD","BK4588","LU2237957902.USD","LU0203347892.USD","LU0708994859.HKD","SGXZ23171101.USD","LU2087625088.SGD","BK4090","IE00B5TLWC47.USD","IE00BZ1G4Q59.USD","BK4534","LU0557290698.USD","IE00B19Z9Z06.USD","IE00BKVL7J92.USD","BK4535","LU0353189680.USD","LU1989764664.SGD","BK7064","BK4561","LU0868494708.USD","SG9999004303.SGD","BK4566","IE00B19Z9P08.USD","LU0994945656.USD","LU0426412945.USD","LU2237957811.SGD","LU1121112475.USD","LU0719512351.SGD","TSI.AU","DOW","LU0823411888.USD"],"gpt_icon":0},{"id":"2505740931","title":"MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=2505740931","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505740931?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:30","pubTimestamp":1737552600,"startTime":"0","endTime":"0","summary":"MeiraGTx has recently received Rare Pediatric Disease Designation  for four inherited retinal diseases  reflecting the transformative therapeutic potential of the Company’s proprietary technology platforms. LONDONandNEW YORK, Jan. 22, 2025  -- MeiraGTx Holdings Plc , a vertically integrated, clinical-stage genetic medicines company, today announced the U.S. Food and Drug Administration  has granted the Company Rare Pediatric Disease Designation to its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations . This is the fourth Rare Pediatric Disease Designation the Company has received in the last three months, including AAV8-RK-AIPL1 for the treatment of LCA4 retinal dystrophy, AAV8-RK-BBS10 for the treatment of Bardet-Biedl syndrome  due toBBS10mutations and AAV5-RDH12 for the treatment ofRDH12 associated retinal dystrophy.“Receiving Rare Pediatric Disease Designation for an additional program in our ophthalmology pipeline represent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiragtx-receives-rare-pediatric-disease-133000804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MGTX","LCA"],"gpt_icon":0},{"id":"2495557562","title":"Hyundai Motor, Kia Unveil Integrated Greenhouse Gas Information System","url":"https://stock-news.laohu8.com/highlight/detail?id=2495557562","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495557562?lang=en_us&edition=fundamental","pubTime":"2024-12-30 09:48","pubTimestamp":1735523293,"startTime":"0","endTime":"0","summary":"Hyundai Motor  and Kia  introduced on Monday the Integrated Greenhouse Gas Information System , a platform designed to monitor, quantify, and manage carbon emissions across a vehicle's lifecycle, Hyundai Motor said in a same-day release.The IGIS uses the life cycle assessment  methodology, ensuring accurate tracking of emissions from production to disposal. The system monitors energy use at global facilities, gathers supplier data to calculate carbon footprints, and predicts emissions across supply chains, the release said.Shares of Kia rose nearly 2% in recent trade on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LCA","III","BK4134"],"gpt_icon":0},{"id":"2492127426","title":"Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for    Phase 3 Trial of APX3330 in Diabetic Retinopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127426","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127426?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"AgreementReached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec.  19, 2024  (GLOBE NEWSWIRE) -- Opus Gen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999786/0/en/Opus-Genetics-Receives-FDA-Agreement-Under-Special-Protocol-Assessment-for-Phase-3-Trial-of-APX3330-in-Diabetic-Retinopathy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009356076.USD","IE00BMPRXN33.USD","IE00B5949003.HKD","LU1880398471.USD","BK4588","LU0823421416.USD","LU1803068979.SGD","BK4534","LU2250418816.HKD","LU0823434740.USD","LU0823421333.USD","BK4573","IE00BMPRXR70.SGD","BK4566","LU1880398554.USD","LU1989764664.SGD","LU0823434583.USD","LU1988902786.USD","LU2098885051.SGD","LU0198837287.USD","LU2264538146.SGD","LU2458330169.SGD","LU1951198990.SGD","LU1852331112.SGD","LU0889565833.HKD","LU0642271901.SGD","BK4585","LU1242518857.USD","SPA","BK4532","LU0081259029.USD","LU1951200564.SGD","LCA","BK4554","LU0719512351.SGD","BK4529","BK4575","LU0109392836.USD","LU0082616367.USD","LU1242518931.SGD","LU2458330243.SGD","LU1303367103.USD","LU0127658192.USD","LU0979878070.USD","BK4512","AMD","BK4141","LU1923623000.USD","LU1316542783.SGD","IE0004445239.USD"],"gpt_icon":1},{"id":"2488147799","title":"Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2488147799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488147799?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:00","pubTimestamp":1733230800,"startTime":"0","endTime":"0","summary":"6-month efficacy and safety data from ongoing Phase 1/2 trial of OPGx-LCA5 to be presentedFARMINGTON HILLS, Mich., Dec.  03, 2024  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-sta","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2990534/0/en/Opus-Genetics-to-Host-Virtual-KOL-Event-on-OPGx-LCA5-as-a-Treatment-for-LCA5-Associated-Inherited-Retinal-Disease-on-December-11-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","LCA","BK4218","BK4181","BK4585","BK4588","BK4007","IRD","KOL"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LCA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-28","symbol":"LCA","reason":null,"defaultRemindTime":1709130600000,"announcedDate":"2024-02-15","type":"delisting","dateTimestamp":1709096400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LCA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LCA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LCA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LCA","date":"2024-02-28","current":54.877481,"percent":0.59733,"low":11.488324,"twenty":30.050032,"median":45.140258,"eighty":66.415048,"high":224.854989,"avg":50.102288,"sd":30.317802,"marketCap":142906832},"quantilePoints":[{"date":"2020-05-01","current":36.842143,"twenty":36.759855,"median":36.842143,"eighty":36.991756,"marketCap":92095520},{"date":"2020-05-08","current":36.879546,"twenty":36.767336,"median":36.842143,"eighty":36.901988,"marketCap":92189018},{"date":"2020-05-15","current":28.446414,"twenty":36.714972,"median":36.842143,"eighty":36.901988,"marketCap":93049870},{"date":"2020-05-22","current":28.560886,"twenty":34.898113,"median":36.842143,"eighty":36.879546,"marketCap":93424316},{"date":"2020-05-29","current":28.475032,"twenty":28.475032,"median":36.842143,"eighty":36.879546,"marketCap":93143482},{"date":"2020-06-05","current":28.417796,"twenty":28.475032,"median":36.767336,"eighty":36.879546,"marketCap":92956259},{"date":"2020-06-12","current":28.532268,"twenty":28.475032,"median":36.748635,"eighty":36.879546,"marketCap":93330705},{"date":"2020-06-19","current":28.789832,"twenty":28.475032,"median":36.655127,"eighty":36.879546,"marketCap":94173209},{"date":"2020-06-26","current":28.875686,"twenty":28.475032,"median":32.729135,"eighty":36.879546,"marketCap":94454043},{"date":"2020-07-02","current":41.353188,"twenty":28.475032,"median":36.617723,"eighty":36.879546,"marketCap":135268675},{"date":"2020-07-10","current":39.264064,"twenty":28.475032,"median":36.655127,"eighty":36.879546,"marketCap":128435032},{"date":"2020-07-17","current":40.294317,"twenty":28.486479,"median":36.655127,"eighty":36.962005,"marketCap":131805048},{"date":"2020-07-24","current":36.345016,"twenty":28.515097,"median":36.729933,"eighty":37.096484,"marketCap":118886655},{"date":"2020-07-31","current":32.910841,"twenty":28.543715,"median":36.617723,"eighty":37.014198,"marketCap":107653271},{"date":"2020-08-07","current":34.885492,"twenty":28.560886,"median":36.345016,"eighty":36.991756,"marketCap":114112467},{"date":"2020-08-14","current":48.972329,"twenty":28.583781,"median":36.316398,"eighty":37.014198,"marketCap":121876505},{"date":"2020-08-21","current":54.665033,"twenty":28.618123,"median":36.58032,"eighty":37.216175,"marketCap":136043828},{"date":"2020-08-28","current":57.643334,"twenty":28.652465,"median":36.69253,"eighty":38.726044,"marketCap":143455871},{"date":"2020-09-04","current":60.810136,"twenty":28.715424,"median":36.767336,"eighty":40.259975,"marketCap":151337031},{"date":"2020-09-11","current":66.87984,"twenty":28.738319,"median":36.80474,"eighty":41.181479,"marketCap":166442587},{"date":"2020-09-18","current":67.40764,"twenty":28.766937,"median":36.842143,"eighty":48.535989,"marketCap":167756114},{"date":"2020-09-25","current":55.984534,"twenty":28.795556,"median":36.842143,"eighty":53.534032,"marketCap":139327645},{"date":"2020-10-02","current":54.891233,"twenty":28.824174,"median":36.860844,"eighty":54.845993,"marketCap":136606768},{"date":"2020-10-09","current":53.157032,"twenty":28.852792,"median":36.879546,"eighty":54.589633,"marketCap":132290895},{"date":"2020-10-16","current":53.119331,"twenty":28.887133,"median":36.879546,"eighty":54.265412,"marketCap":132197071},{"date":"2020-10-23","current":46.182528,"twenty":28.938646,"median":36.879546,"eighty":54.091992,"marketCap":114933579},{"date":"2020-10-30","current":46.748028,"twenty":28.967264,"median":36.954567,"eighty":53.722532,"marketCap":116340929},{"date":"2020-11-06","current":50.66883,"twenty":29.711336,"median":37.029159,"eighty":53.534032,"marketCap":126098555},{"date":"2020-11-13","current":117.235104,"twenty":32.659002,"median":37.195559,"eighty":53.534032,"marketCap":125109083},{"date":"2020-11-20","current":127.732453,"twenty":33.025314,"median":37.403191,"eighty":54.589633,"marketCap":136311476},{"date":"2020-11-27","current":176.426041,"twenty":33.483204,"median":37.919013,"eighty":55.720633,"marketCap":188275520},{"date":"2020-12-04","current":206.242042,"twenty":33.626294,"median":39.349919,"eighty":57.190934,"marketCap":220094082},{"date":"2020-12-11","current":195.480054,"twenty":33.941094,"median":40.294317,"eighty":59.716836,"marketCap":208609276},{"date":"2020-12-18","current":206.77132,"twenty":34.084184,"median":41.138551,"eighty":61.828037,"marketCap":220658909},{"date":"2020-12-24","current":224.854989,"twenty":34.656546,"median":41.496279,"eighty":63.916618,"marketCap":239957150},{"date":"2020-12-28","current":224.854989,"twenty":34.799637,"median":41.639369,"eighty":66.238939,"marketCap":239957150},{"date":"2021-03-26","current":67.434726,"twenty":34.822532,"median":44.259826,"eighty":66.87984,"marketCap":620000000},{"date":"2021-04-01","current":67.638662,"twenty":34.862598,"median":45.767827,"eighty":67.342317,"marketCap":621875000},{"date":"2021-04-09","current":67.910576,"twenty":34.954175,"median":46.295628,"eighty":67.665854,"marketCap":624375000},{"date":"2021-04-16","current":68.114512,"twenty":35.12016,"median":46.790631,"eighty":67.835015,"marketCap":626250000},{"date":"2021-04-23","current":67.978555,"twenty":35.320487,"median":47.879029,"eighty":67.947013,"marketCap":625000000},{"date":"2021-04-30","current":67.978555,"twenty":35.45213,"median":49.123129,"eighty":67.978555,"marketCap":625000000},{"date":"2021-05-07","current":67.842598,"twenty":35.486472,"median":50.06563,"eighty":67.978555,"marketCap":623750000},{"date":"2021-05-14","current":68.046533,"twenty":35.572327,"median":50.51803,"eighty":67.978555,"marketCap":625625000},{"date":"2021-05-21","current":65.39537,"twenty":35.938639,"median":50.78193,"eighty":67.978555,"marketCap":601250000},{"date":"2021-05-28","current":67.570684,"twenty":36.230544,"median":51.083531,"eighty":67.978555,"marketCap":621250000},{"date":"2021-06-04","current":67.638662,"twenty":36.310674,"median":51.837531,"eighty":67.978555,"marketCap":621875000},{"date":"2021-06-11","current":66.143134,"twenty":36.394254,"median":52.459581,"eighty":67.978555,"marketCap":608125000},{"date":"2021-06-18","current":66.483027,"twenty":36.512995,"median":53.157032,"eighty":67.978555,"marketCap":611250000},{"date":"2021-06-25","current":67.026855,"twenty":36.610243,"median":53.477482,"eighty":67.978555,"marketCap":616250000},{"date":"2021-07-02","current":66.279091,"twenty":36.655127,"median":54.174932,"eighty":67.978555,"marketCap":609375000},{"date":"2021-07-09","current":65.939198,"twenty":36.670088,"median":54.665033,"eighty":67.978555,"marketCap":606250000},{"date":"2021-07-16","current":66.007177,"twenty":36.737414,"median":55.362483,"eighty":67.972981,"marketCap":606875000},{"date":"2021-07-23","current":66.279091,"twenty":36.767336,"median":56.851634,"eighty":67.94946,"marketCap":609375000},{"date":"2021-07-30","current":65.939198,"twenty":36.767336,"median":57.247484,"eighty":67.937768,"marketCap":606250000},{"date":"2021-08-06","current":65.938518,"twenty":36.774817,"median":58.284235,"eighty":67.910576,"marketCap":606243750},{"date":"2021-08-13","current":65.939198,"twenty":36.812221,"median":60.546236,"eighty":67.910576,"marketCap":606250000},{"date":"2021-08-20","current":65.599305,"twenty":36.842143,"median":61.828037,"eighty":67.89698,"marketCap":603125000},{"date":"2021-08-27","current":65.905209,"twenty":36.842143,"median":63.147538,"eighty":67.842598,"marketCap":605937500},{"date":"2021-09-03","current":66.483027,"twenty":36.842143,"median":65.327391,"eighty":67.831007,"marketCap":611250000},{"date":"2021-09-10","current":66.285889,"twenty":36.842143,"median":65.39537,"eighty":67.784641,"marketCap":609437500},{"date":"2021-09-17","current":66.415048,"twenty":36.842143,"median":65.599305,"eighty":67.774619,"marketCap":610625000},{"date":"2021-09-24","current":66.34707,"twenty":36.842143,"median":65.599305,"eighty":67.706641,"marketCap":610000000},{"date":"2021-10-01","current":66.279091,"twenty":36.842143,"median":65.673742,"eighty":67.706641,"marketCap":609375000},{"date":"2021-10-08","current":66.34707,"twenty":36.879546,"median":65.735263,"eighty":67.638662,"marketCap":610000000},{"date":"2021-10-15","current":66.618984,"twenty":36.879546,"median":65.921864,"eighty":67.638662,"marketCap":612500000},{"date":"2021-10-22","current":66.143134,"twenty":36.879546,"median":65.939198,"eighty":67.638662,"marketCap":608125000},{"date":"2021-10-29","current":66.279771,"twenty":36.879546,"median":65.939198,"eighty":67.638662,"marketCap":609381250},{"date":"2021-11-05","current":66.754941,"twenty":36.879546,"median":65.939198,"eighty":67.570684,"marketCap":613750000},{"date":"2021-11-12","current":66.618984,"twenty":36.879546,"median":65.939198,"eighty":67.570684,"marketCap":612500000},{"date":"2021-11-19","current":66.618984,"twenty":36.879546,"median":65.939198,"eighty":67.502705,"marketCap":612500000},{"date":"2021-11-26","current":66.686962,"twenty":36.879546,"median":65.939198,"eighty":67.448322,"marketCap":613125000},{"date":"2021-12-03","current":66.618984,"twenty":36.879546,"median":65.984744,"eighty":67.434726,"marketCap":612500000},{"date":"2021-12-10","current":66.483027,"twenty":36.909812,"median":66.007177,"eighty":67.427112,"marketCap":611250000},{"date":"2021-12-17","current":66.211112,"twenty":36.97688,"median":66.007177,"eighty":67.411154,"marketCap":608750000},{"date":"2021-12-23","current":66.34707,"twenty":36.991756,"median":66.075155,"eighty":67.342317,"marketCap":610000000},{"date":"2021-12-31","current":66.143134,"twenty":37.014198,"median":66.143134,"eighty":67.298769,"marketCap":608125000},{"date":"2022-01-07","current":66.618984,"twenty":37.096484,"median":66.143134,"eighty":67.257982,"marketCap":612500000},{"date":"2022-01-14","current":66.143134,"twenty":37.161512,"median":66.143134,"eighty":67.108429,"marketCap":608125000},{"date":"2022-01-21","current":65.803241,"twenty":37.191435,"median":66.143134,"eighty":67.026855,"marketCap":605000000},{"date":"2022-01-28","current":65.803241,"twenty":37.216175,"median":66.143134,"eighty":67.026855,"marketCap":605000000},{"date":"2022-02-04","current":66.007177,"twenty":37.290981,"median":66.075155,"eighty":67.026855,"marketCap":606875000},{"date":"2022-02-11","current":66.007177,"twenty":37.506495,"median":66.075155,"eighty":66.999664,"marketCap":606875000},{"date":"2022-02-18","current":65.939198,"twenty":37.764475,"median":66.075155,"eighty":66.931685,"marketCap":606250000},{"date":"2022-02-25","current":66.007177,"twenty":38.188023,"median":66.041166,"eighty":66.890898,"marketCap":606875000},{"date":"2022-03-04","current":66.007177,"twenty":39.281235,"median":66.007177,"eighty":66.888686,"marketCap":606875000},{"date":"2022-03-11","current":66.279091,"twenty":39.349919,"median":66.041166,"eighty":66.87984,"marketCap":609375000},{"date":"2022-03-18","current":66.280451,"twenty":39.521628,"median":66.075155,"eighty":66.868456,"marketCap":609387500},{"date":"2022-03-25","current":66.34707,"twenty":40.225634,"median":66.075155,"eighty":66.816121,"marketCap":610000000},{"date":"2022-04-01","current":66.551005,"twenty":40.334382,"median":66.09215,"eighty":66.782132,"marketCap":611875000},{"date":"2022-04-08","current":66.551005,"twenty":40.609116,"median":66.143134,"eighty":66.754941,"marketCap":611875000},{"date":"2022-04-14","current":66.618984,"twenty":41.067006,"median":66.143134,"eighty":66.754941,"marketCap":612500000},{"date":"2022-04-22","current":66.686962,"twenty":41.210097,"median":66.143134,"eighty":66.754941,"marketCap":613125000},{"date":"2022-04-29","current":66.483027,"twenty":41.353188,"median":66.143134,"eighty":66.754941,"marketCap":611250000},{"date":"2022-05-06","current":66.551005,"twenty":41.639369,"median":66.143134,"eighty":66.754941,"marketCap":611875000},{"date":"2022-05-13","current":30.050032,"twenty":41.639369,"median":66.143134,"eighty":66.754941,"marketCap":610625000},{"date":"2022-05-20","current":29.927002,"twenty":40.494644,"median":66.143134,"eighty":66.754941,"marketCap":608125000},{"date":"2022-05-27","current":29.957759,"twenty":39.349919,"median":66.143134,"eighty":66.754941,"marketCap":608750000},{"date":"2022-06-03","current":29.957759,"twenty":37.609798,"median":66.143134,"eighty":66.754941,"marketCap":608750000},{"date":"2022-06-10","current":30.173062,"twenty":37.168227,"median":66.143134,"eighty":66.73422,"marketCap":613125000},{"date":"2022-06-17","current":30.050032,"twenty":36.97688,"median":66.143134,"eighty":66.72257,"marketCap":610625000},{"date":"2022-06-24","current":30.111547,"twenty":36.879546,"median":66.075155,"eighty":66.700558,"marketCap":611875000},{"date":"2022-07-01","current":30.111547,"twenty":36.879546,"median":66.075155,"eighty":66.686962,"marketCap":611875000},{"date":"2022-07-08","current":30.050032,"twenty":36.857104,"median":66.075155,"eighty":66.686962,"marketCap":610625000},{"date":"2022-07-15","current":30.050032,"twenty":36.842143,"median":66.041166,"eighty":66.686962,"marketCap":610625000},{"date":"2022-07-22","current":30.111547,"twenty":36.782298,"median":66.007177,"eighty":66.686962,"marketCap":611875000},{"date":"2022-07-29","current":30.111547,"twenty":36.685049,"median":66.007177,"eighty":66.686962,"marketCap":611875000},{"date":"2022-08-05","current":30.203819,"twenty":36.394254,"median":66.007177,"eighty":66.686962,"marketCap":613750000},{"date":"2022-08-12","current":30.203819,"twenty":35.543708,"median":66.007177,"eighty":66.686962,"marketCap":613750000},{"date":"2022-08-19","current":44.594207,"twenty":35.835613,"median":66.007177,"eighty":66.686962,"marketCap":612500000},{"date":"2022-08-26","current":44.639711,"twenty":36.201925,"median":66.007177,"eighty":66.686962,"marketCap":613125000},{"date":"2022-09-02","current":44.594207,"twenty":36.310674,"median":65.988823,"eighty":66.686962,"marketCap":612500000},{"date":"2022-09-09","current":44.616959,"twenty":36.369635,"median":65.96503,"eighty":66.686962,"marketCap":612812500},{"date":"2022-09-16","current":44.639711,"twenty":36.490553,"median":65.939198,"eighty":66.686962,"marketCap":613125000},{"date":"2022-09-23","current":44.685215,"twenty":36.595281,"median":65.939198,"eighty":66.673366,"marketCap":613750000},{"date":"2022-09-30","current":44.685215,"twenty":36.655127,"median":65.939198,"eighty":66.618984,"marketCap":613750000},{"date":"2022-10-07","current":44.867232,"twenty":36.670088,"median":65.939198,"eighty":66.618984,"marketCap":616250000},{"date":"2022-10-14","current":44.969617,"twenty":36.737414,"median":65.939198,"eighty":66.618984,"marketCap":617656250},{"date":"2022-10-21","current":45.049249,"twenty":36.767336,"median":65.939198,"eighty":66.618984,"marketCap":618750000},{"date":"2022-10-28","current":45.140258,"twenty":36.767336,"median":65.939198,"eighty":66.618984,"marketCap":620000000},{"date":"2022-11-04","current":45.185762,"twenty":36.774817,"median":65.939198,"eighty":66.618984,"marketCap":620625000},{"date":"2022-11-11","current":45.140713,"twenty":36.812221,"median":65.939198,"eighty":66.618984,"marketCap":620006250},{"date":"2022-11-18","current":33.101263,"twenty":36.737414,"median":65.888215,"eighty":66.618984,"marketCap":625000000},{"date":"2022-11-25","current":33.167465,"twenty":36.58032,"median":65.837231,"eighty":66.618984,"marketCap":626250000},{"date":"2022-12-02","current":33.233668,"twenty":36.144689,"median":65.803241,"eighty":66.618984,"marketCap":627500000},{"date":"2022-12-09","current":33.266769,"twenty":35.400618,"median":65.742061,"eighty":66.618984,"marketCap":628125000},{"date":"2022-12-16","current":33.266769,"twenty":34.828256,"median":65.735263,"eighty":66.618984,"marketCap":628125000},{"date":"2022-12-23","current":33.03506,"twenty":33.626294,"median":65.633634,"eighty":66.618984,"marketCap":623750000},{"date":"2022-12-30","current":33.167465,"twenty":33.311522,"median":65.599305,"eighty":66.618984,"marketCap":626250000},{"date":"2023-01-06","current":33.051611,"twenty":33.266769,"median":65.599305,"eighty":66.618984,"marketCap":624062500},{"date":"2023-01-13","current":33.001959,"twenty":33.253529,"median":65.39537,"eighty":66.618984,"marketCap":623125000},{"date":"2023-01-20","current":33.167465,"twenty":33.193218,"median":65.327391,"eighty":66.618984,"marketCap":626250000},{"date":"2023-01-27","current":33.233668,"twenty":33.167465,"median":63.147538,"eighty":66.618984,"marketCap":627500000},{"date":"2023-02-03","current":33.134364,"twenty":33.167465,"median":61.828037,"eighty":66.618984,"marketCap":625625000},{"date":"2023-02-10","current":33.134364,"twenty":33.147604,"median":60.546236,"eighty":66.618984,"marketCap":625625000},{"date":"2023-02-17","current":33.399174,"twenty":33.167465,"median":58.284235,"eighty":66.618984,"marketCap":630625000},{"date":"2023-02-24","current":33.233668,"twenty":33.167465,"median":57.304034,"eighty":66.618984,"marketCap":627500000},{"date":"2023-03-03","current":33.332971,"twenty":33.167465,"median":56.983584,"eighty":66.605388,"marketCap":629375000},{"date":"2023-03-10","current":33.29987,"twenty":33.167465,"median":55.720633,"eighty":66.551005,"marketCap":628750000},{"date":"2023-03-17","current":33.366073,"twenty":33.167465,"median":54.778133,"eighty":66.551005,"marketCap":630000000},{"date":"2023-03-24","current":33.233999,"twenty":33.167465,"median":54.174932,"eighty":66.551005,"marketCap":627506250},{"date":"2023-03-31","current":33.399174,"twenty":33.167465,"median":53.477482,"eighty":66.551005,"marketCap":630625000},{"date":"2023-04-06","current":33.332971,"twenty":33.167465,"median":53.251282,"eighty":66.551005,"marketCap":629375000},{"date":"2023-04-14","current":33.399174,"twenty":33.184016,"median":52.591531,"eighty":66.551005,"marketCap":630625000},{"date":"2023-04-21","current":33.399174,"twenty":33.188319,"median":51.931781,"eighty":66.551005,"marketCap":630625000},{"date":"2023-04-28","current":26.2563,"twenty":33.167465,"median":51.083531,"eighty":66.551005,"marketCap":629375000},{"date":"2023-05-05","current":26.2563,"twenty":33.167465,"median":50.78193,"eighty":66.551005,"marketCap":629375000},{"date":"2023-05-12","current":26.334521,"twenty":33.134364,"median":50.51803,"eighty":66.551005,"marketCap":631250000},{"date":"2023-05-19","current":51.891527,"twenty":33.134364,"median":50.63113,"eighty":66.551005,"marketCap":630937500},{"date":"2023-05-26","current":11.488324,"twenty":33.134364,"median":50.89503,"eighty":66.489825,"marketCap":139683972},{"date":"2023-06-02","current":11.522516,"twenty":33.134364,"median":50.59343,"eighty":66.484387,"marketCap":140099699},{"date":"2023-06-09","current":11.522516,"twenty":33.101263,"median":50.25413,"eighty":66.483027,"marketCap":140099699},{"date":"2023-06-16","current":11.522516,"twenty":33.064851,"median":49.160829,"eighty":66.483027,"marketCap":140099699},{"date":"2023-06-23","current":11.533913,"twenty":33.051611,"median":48.972329,"eighty":66.483027,"marketCap":140238274},{"date":"2023-06-30","current":11.556707,"twenty":33.049625,"median":47.879029,"eighty":66.483027,"marketCap":140515425},{"date":"2023-07-07","current":11.556707,"twenty":33.03506,"median":46.790631,"eighty":66.483027,"marketCap":140515425},{"date":"2023-07-14","current":11.619619,"twenty":33.008579,"median":46.295628,"eighty":66.483027,"marketCap":141280361},{"date":"2023-07-21","current":11.619619,"twenty":32.935756,"median":45.880927,"eighty":66.483027,"marketCap":141280361},{"date":"2023-07-28","current":11.659281,"twenty":32.869554,"median":45.185762,"eighty":66.483027,"marketCap":141762603},{"date":"2023-08-04","current":11.659281,"twenty":32.720598,"median":45.185762,"eighty":66.483027,"marketCap":141762603},{"date":"2023-08-11","current":11.647998,"twenty":30.203819,"median":45.185762,"eighty":66.483027,"marketCap":141625413},{"date":"2023-08-18","current":18.12164,"twenty":30.173062,"median":45.140258,"eighty":66.483027,"marketCap":142316904},{"date":"2023-08-25","current":18.174576,"twenty":30.142304,"median":45.128882,"eighty":66.483027,"marketCap":142732631},{"date":"2023-09-01","current":18.262625,"twenty":30.117698,"median":45.094754,"eighty":66.483027,"marketCap":143424122},{"date":"2023-09-08","current":18.262802,"twenty":30.111547,"median":45.094754,"eighty":66.483027,"marketCap":143425507},{"date":"2023-09-14","current":18.280447,"twenty":30.111547,"median":45.049249,"eighty":66.483027,"marketCap":143564083},{"date":"2023-09-22","current":18.52748,"twenty":30.111547,"median":45.049249,"eighty":66.483027,"marketCap":145504138},{"date":"2023-09-29","current":18.368673,"twenty":30.111547,"median":45.049249,"eighty":66.483027,"marketCap":144256960},{"date":"2023-10-06","current":18.403963,"twenty":30.080789,"median":44.969617,"eighty":66.483027,"marketCap":144534110},{"date":"2023-10-13","current":18.392494,"twenty":30.080789,"median":44.889984,"eighty":66.483027,"marketCap":144444036},{"date":"2023-10-20","current":18.351028,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":144118384},{"date":"2023-10-27","current":18.351204,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":144119770},{"date":"2023-11-03","current":18.368673,"twenty":30.050032,"median":44.730719,"eighty":66.483027,"marketCap":144256960},{"date":"2023-11-10","current":18.368673,"twenty":30.050032,"median":44.707967,"eighty":66.483027,"marketCap":144256960},{"date":"2023-11-17","current":18.298269,"twenty":30.032869,"median":44.696591,"eighty":66.483027,"marketCap":143704044},{"date":"2023-11-24","current":54.096492,"twenty":30.050032,"median":44.707967,"eighty":66.483027,"marketCap":140873053},{"date":"2023-11-30","current":54.200624,"twenty":30.050032,"median":44.730719,"eighty":66.483027,"marketCap":141144224},{"date":"2023-12-22","current":54.096492,"twenty":30.050032,"median":44.730719,"eighty":66.483027,"marketCap":140873053},{"date":"2023-12-29","current":54.25269,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":141279809},{"date":"2024-01-05","current":54.25269,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":141279809},{"date":"2024-01-12","current":54.513019,"twenty":30.050032,"median":44.889984,"eighty":66.428644,"marketCap":141957735},{"date":"2024-01-19","current":54.513019,"twenty":30.050032,"median":44.963929,"eighty":66.415048,"marketCap":141957735},{"date":"2024-01-26","current":54.877481,"twenty":30.050032,"median":45.049249,"eighty":66.415048,"marketCap":142906832},{"date":"2024-02-02","current":54.877481,"twenty":30.050032,"median":45.049249,"eighty":66.415048,"marketCap":142906832},{"date":"2024-02-09","current":54.513019,"twenty":30.050032,"median":45.049249,"eighty":66.415048,"marketCap":141957735},{"date":"2024-02-16","current":54.773349,"twenty":30.050032,"median":45.094754,"eighty":66.415048,"marketCap":142635661},{"date":"2024-02-23","current":54.877481,"twenty":30.050032,"median":45.128882,"eighty":66.415048,"marketCap":142906832},{"date":"2024-02-28","current":54.877481,"twenty":30.050032,"median":45.140258,"eighty":66.415048,"marketCap":142906832}],"updateTime":1745625905880}}}